一个阶段的单个和多重上升剂量研究 orforglipron 在日本参与者患有2型糖尿病
Kenji Ohwaki1, Chino Nakamura2, Risa Nasu1
1Eli Lilly Japan K.K., Kobe, Japan.
Journal of diabetes investigation
|December 1, 2025
概括
在日本2型糖尿病患者中,Orforglipron表现出良好的安全性和耐受性. 这种口服的葡萄糖类-1受体激动剂显示出葡萄糖和体重的显著降低,表明其作为一种新的治疗选择的潜力.
科学领域:
- 药理学和内分泌学 药理学和内分泌学
- 临床试验和治疗方法
背景情况:
- 2型糖尿病 (T2DM) 仍然是一个重大的全球健康挑战.
- 需要新的治疗药物来改善T2DM患者的血糖控制和体重管理.
研究的目的:
- 评估日本参与者T2DM的orforglipron的安全性,耐受性,药理动力学和药理动力学.
- 为了评估单次和多次口服剂量的orforglipron.
主要方法:
- 一个双盲,安慰剂控制,随机的第一阶段研究.
- 部分A:单剂 orforglipron (2或3毫克) 或安慰剂.
- 部分B:多次上升剂量 (12,24,45毫克) 或安慰剂为12周.
主要成果:
- 奥尔福格利普朗在一般情况下是安全的,耐受性很好,最常见的是轻微的胃肠道事件.
- 药理动力学分析显示Tmax的中位数为5.92-8.00小时,平均终端半衰期为51.8-76.1小时.
- 与安慰剂相比,多次剂量导致禁食葡萄糖,HbA1c和体重显著降低.
结论:
- 甲福格利的安全性和药用动力学概况与之前的研究和其他GLP-1受体激动剂相一致.
- 对于日本2型糖尿病患者来说,Orforglipron是一种有前途的口服治疗选择.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
565
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
565
Bioavailability Study Design: Single Versus Multiple Dose Studies
181
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
181
Oral Hypoglycemic Agents: Glinides
572
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
572
Bioavailability Study Design: Healthy Subjects Versus Patients
135
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
135
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
509
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
509
Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K


